Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | PRDM2 |
| Gene Name: | PRDM2 |
| Protein Full Name: | PR domain zinc finger protein 2 |
| Alias: | GATA-3 binding protein G3B; GATA-3-binding protein G3B; HUMHOXY1; KMT8; Lysine N-methyltransferase 8; MTB-ZF; MTE-binding protein; PR domain containing 2, with ZNF domain; PR domain zinc finger protein 2: PR domain-containing protein 2: Retinoblastoma protein-interacting zinc finger protein: Zinc finger protein RIZ: MTE-binding protein: MTB-ZF: GATA-3-binding protein G3B: Lysine N-methyltransferase 8: Putative uncharacterized protein PRDM2: PR domain zinc finger protein 2: PR domain-containing protein 2: Retinoblastoma protein-interacting zinc finger protein: Zinc finger protein RIZ: MTE-binding protein: MTB-ZF: GATA-3-binding protein G3B: Lysine N-methyltransferase 8: PR domain zinc finger protein 2: PR domain-containing protein 2: Retinoblastoma protein-interacting zinc finger protein: Zinc finger protein RIZ: MTE-binding protein: MTB-ZF: GATA-3-binding protein G3B: Lysine N-methyltransferase 8: Putative uncharacterized protein PRDM2: PR domain containing 2, with ZNF domain; PRD2; PRDM2; PR-domain zinc finger protein 2; Retinoblastoma protein-binding zinc finger protein; Retinoblastoma protein-interacting zinc finger protein; Retinoblastoma protein-interacting zinc-finger protein; RIZ1; RIZ2; Zinc finger protein RIZ; Zinc-finger DNA-binding protein |
| Mass (Da): | 188915 |
| Number AA: | 1718 |
| UniProt ID: | Q13029 |
| Locus ID: | 7799 |
| COSMIC ID: | PRDM2 |
| Gene location on chromosome: | 1p36.21 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19651 |
| Percent of cancer specimens with mutations: | 1.45 |
| Gene undergoes hypermethylation: | Ovarian and prostate cancer |
| Normal role description: | Histone methyltransferase that specifically methylates 'Lys-9' of histone H3. Has DNA-binding and transcription factor-binding activity. Activates heme-oxygenase-1 gene transcription and interacts with the transcription factor GATA-3, regulating the expression of several genes critical for T-cell function and development. Estradiol binding to estrogen receptor complex converts PRDM2 from a transcriptional repressor into a co-activator. Expression is downregulated in various human cancers. It is suggested to be a tumour suppressor and it could be a predictive marker for lung cancer susceptibility. |